PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2006; 8(4): 110.
Published online Jun 22, 2006. doi:  10.1186/ar1987
PMCID: PMC1779402
The RNA interference pathway: a new target for autoimmunity
Ger JM Pruijncorresponding author1
1Department of Biochemistry, Radboud University Nijmegen, Nijmegen, The Netherlands
corresponding authorCorresponding author.
Ger JM Pruijn: G.Pruijn/at/ncmls.ru.nl
Abstract
Many intracellular macromolecular complexes that are involved in the production or degradation of RNAs are targeted by autoantibodies in systemic autoimmune diseases. RNA interference (RNAi) is a recently characterized gene silencing pathway by which specific mRNAs are either degraded or translationally suppressed. In a recent issue of Arthritis Research and Therapy, Andrew Jakymiw and colleagues reported that the enigmatic Su autoantigen complex contains key components of the RNAi machinery. Anti-Su autoantibodies from both human patients with rheumatic diseases and a mouse model of autoimmunity recognize the endonucleolytic Argonaute and Dicer proteins, both crucial enzymes of the RNAi pathway. These data raise the question of how the anti-Su response is triggered. So far, it is unknown whether molecular modifications may be involved, as has been proposed for other intracellular autoantigens. The implication of RNAi in anti-viral defence may suggest a role for virus infection in this process.
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central